Management of patients with non-Hodgkin’s lymphoma: focus on adoptive T-cell therapy

References

• ShanklandKRArmitageJOHancockBWNon-Hodgkin lymphomaLancet201238084885722835603
   PubMed Web of Science ®Google Scholar
• LeechawengwongsEShearerWTLymphoma complicating primary immunodeficiency syndromesCurr Opin Hematol20121930531222525579
   PubMed Web of Science ®Google Scholar
• ZelenetzADWierdaWGAbramsonJSNon-Hodgkin’s lymphomas, version 1.2013J Natl Compr Canc Netw20131125727223486452
   PubMed Web of Science ®Google Scholar
• AbramsonJSZelenetzADRecent advances in the treatment of non-Hodgkin’s lymphomasJ Natl Compr Canc Netw20131167167523704240
   PubMed Web of Science ®Google Scholar
• GangatharanSKuruvillaJRelapsed and refractory aggressive NHL: time for a changeTransfus Apher Sci201349727923835116
   PubMed Web of Science ®Google Scholar
• HarrisonAMThaljiNMGreenbergAJTapiaCJWindebankAJRituximab for non-Hodgkin’s lymphoma: a story of rapid success in translationClin Transl Sci20147828624528902
   PubMed Web of Science ®Google Scholar
• GisselbrechtCIs there any role for transplantation in the rituximab era for diffuse large B-cell lymphoma?Hematology Am Soc Hematol Educ Program2012201241041623233612
   PubMed Web of Science ®Google Scholar
• RodriguesCAPatahPANovisYAHosingCde LimaMThe role of transplantation in diffuse large B-cell lymphoma: the impact of rituximab plus chemotherapy in first-line and relapsed settingsCurr Hematol Malig Rep20116475721190142
   PubMed Web of Science ®Google Scholar
• ChaoMPTreatment challenges in the management of relapsed or refractory non-Hodgkin’s lymphoma – novel and emerging therapiesCancer Manag Res2013525126924049458
   PubMedGoogle Scholar
• HorwitzSMAdvaniRHBartlettNLObjective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotinBlood20141233095310024652992
   PubMed Web of Science ®Google Scholar
• SchlegelPLangPZugmaierGPediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomabHaematologica2014991212121924727818
   PubMed Web of Science ®Google Scholar
• BollardCMRooneyCMHeslopHET-cell therapy in the treatment of post-transplant lymphoproliferative diseaseNat Rev Clin Oncol2012951051922801669
   PubMed Web of Science ®Google Scholar
• PapadopoulosEBLadanyiMEmanuelDInfusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantationN Engl J Med1994330118511918093146
   PubMed Web of Science ®Google Scholar
• RooneyCMSmithCANgCYUse of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferationLancet19953459137799740
   PubMed Web of Science ®Google Scholar
• BollardCMGottschalkSTorranoVSustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteinsJ Clin Oncol20143279880824344220
   PubMed Web of Science ®Google Scholar
• BollardCMGottschalkSLeenAMComplete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transferBlood20071102838284517609424
   PubMed Web of Science ®Google Scholar
• NgoMCAndoJLeenAMComplementation of antigen-presenting cells to generate T lymphocytes with broad target specificityJ Immunother20143719320324714353
   PubMed Web of Science ®Google Scholar
• NishikawaHMaedaYIshidaTCancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphomaBlood20121193097310422323448
   PubMed Web of Science ®Google Scholar
• TurtleCJRiddellSRArtificial antigen-presenting cells for use in adoptive immunotherapyCancer J20101637438120693850
   PubMed Web of Science ®Google Scholar
• ButlerMOFriedlanderPMilsteinMIEstablishment of antitumor memory in humans using in vitro-educated CD8+ T cellsSci Transl Med2011380ra34
   PubMed Web of Science ®Google Scholar
• ChapuisAGThompsonJAMargolinKATransferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotypeProc Natl Acad Sci USA20121094592459722393002
   PubMed Web of Science ®Google Scholar
• ChapuisAGRagnarssonGBNguyenHNTransferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patientsSci Transl Med20135174ra27
   PubMed Web of Science ®Google Scholar
• GerdemannUKatariUChristinASCytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphomaMol Ther2011192258226821915103
   PubMed Web of Science ®Google Scholar
• MorganRADudleyMEWunderlichJRCancer regression in patients after transfer of genetically engineered lymphocytesScience200631412612916946036
   PubMed Web of Science ®Google Scholar
• MausMVGruppSAPorterDLJuneCHAntibody-modified T cells: CARs take the front seat for hematologic malignanciesBlood20141232625263524578504
   PubMed Web of Science ®Google Scholar
• LinetteGPStadtmauerEAMausMVCardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanomaBlood201312286387123770775
   PubMed Web of Science ®Google Scholar
• EshharZWaksTGrossGSchindlerDGSpecific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptorsProc Natl Acad Sci USA1993907207248421711
   PubMed Web of Science ®Google Scholar
• TillBGJensenMCWangJCD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial resultsBlood20121193940395022308288
   PubMed Web of Science ®Google Scholar
• KochenderferJNWilsonWHJanikJEEradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19Blood20101164099410220668228
   PubMed Web of Science ®Google Scholar
• VeraJSavoldoBVigourouxST lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cellsBlood20061083890389716926291
   PubMed Web of Science ®Google Scholar
• BeattyGLHaasARMausMVMesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignanciesCancer Immunol Res2014211212024579088
   PubMed Web of Science ®Google Scholar
• BuddeLEBergerCLinYCombining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphomaPLoS One20138e8274224358223
   PubMed Web of Science ®Google Scholar
• LeeDWGardnerRPorterDLCurrent concepts in the diagnosis and management of cytokine release syndromeBlood201412418819524876563
   PubMed Web of Science ®Google Scholar
• MaudeSLBarrettDTeacheyDTGruppSAManaging cytokine release syndrome associated with novel T cell-engaging therapiesCancer J20142011912224667956
   PubMed Web of Science ®Google Scholar
• RossilleDGressierMDamotteDHigh level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trialLeukemia Epub4152014
   PubMed Web of Science ®Google Scholar
• LiuXQLuKFengLLUp-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltrationLeuk Lymphoma20145540541423682557
   PubMed Web of Science ®Google Scholar
• BossardCBelhadjKReyesFExpression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d’Etude des Lymphomes de l’Adulte (GELA) trialsBlood20071092183218917077322
   PubMed Web of Science ®Google Scholar
• BladergroenBAMeijerCJten BergeRLExpression of the granzyme B inhibitor, protease inhibitor 9, by tumor cells in patients with non-Hodgkin and Hodgkin lymphoma: a novel protective mechanism for tumor cells to circumvent the immune system?Blood20029923223711756176
   PubMed Web of Science ®Google Scholar
• TaubeJMKleinAPBrahmerJRAssociation of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapyClin Cancer Res Epub482014
   Web of Science ®Google Scholar
• XuYZhangMRamosCAClosely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15Blood20141233750375924782509
   PubMed Web of Science ®Google Scholar
• WangXNaranjoABrownCEPhenotypic and functional attributes of lentivirus-modified CD19-specific human CD8 central memory T cells manufactured at clinical scaleJ Immunother20123568970123090078
   PubMed Web of Science ®Google Scholar
• PapadopoulouAGerdemannUKatariULActivity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCTSci Transl Med20146242ra83
   PubMed Web of Science ®Google Scholar
• SavoldoBRamosCALiuECD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patientsJ Clin Invest20111211822182621540550
   PubMed Web of Science ®Google Scholar
• KochenderferJNWilsonWHJanikJEEradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19Blood20101164099410220668228
   PubMed Web of Science ®Google Scholar
• KochenderferJNDudleyMEFeldmanSAB-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cellsBlood20121192709272022160384
   PubMed Web of Science ®Google Scholar
• KochenderferJNDudleyMECarpenterRODonor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantationBlood20131224129413924055823
   PubMed Web of Science ®Google Scholar
• TillBGJensenMCWangJAdoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cellsBlood20081122261227118509084
   PubMed Web of Science ®Google Scholar
• JensenMCPopplewellLCooperLJAntitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humansBiol Blood Marrow Transplant2010161245125620304086
   PubMed Web of Science ®Google Scholar